(VIANEWS) – Neurocrine Biosciences (NBIX), Syneos Health (SYNH), Anthem (ANTM) are the highest sales growth and return on equity stocks on this list.

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. Neurocrine Biosciences (NBIX)

31.4% sales growth and 41.37% return on equity

Neurocrine Biosciences, Inc., a neuroscience-focused biopharmaceutical company, discovers, develops, and delivers various treatments for people with neurological, endocrine, and psychiatric disorders.

Neurocrine Biosciences’s sales growth this year is anticipated to be 9% and 22.5% for next year.

Year-on-year quarterly revenue growth grew by 14.5%, now sitting on 1.07B for the twelve trailing months.

Volume

Today’s last reported volume for Neurocrine Biosciences is 2262440 which is 176.07% above its average volume of 819519.

Neurocrine Biosciences’s sales growth for the next quarter is 31.4%. The company’s growth estimates for the current quarter and the next is a negative 83.5% and 42.4%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 41.37%.

Volatility

Neurocrine Biosciences’s last day, last week, and last month’s current intraday variation average was 9.57%, 4.10%, and 1.94%, respectively.

Neurocrine Biosciences’s highest amplitude of average volatility was 7.49% (day), 5.12% (last week), and 3.68% (last month), respectively.

Neurocrine Biosciences’s Stock Yearly Top and Bottom Value

Neurocrine Biosciences’s stock is valued at $75.32 at 19:22 EST, way below its 52-week high of $120.27 and higher than its 52-week low of $75.16.

Neurocrine Biosciences’s Moving Average

Neurocrine Biosciences’s worth is way under its 50-day moving average of $86.96 and way under its 200-day moving average of $93.89.

2. Syneos Health (SYNH)

23.5% sales growth and 6.37% return on equity

Syneos Health, Inc. operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America.

Syneos Health’s sales growth this year is anticipated to be 18.8% and 8.5% for next year.

Year-on-year quarterly revenue growth grew by 3.9%, now sitting on 4.46B for the twelve trailing months.

Volume

Today’s last reported volume for Syneos Health is 86776 which is 84.73% below its average volume of 568425.

Syneos Health’s sales growth for the next quarter is 23.5%. The company’s growth estimates for the ongoing quarter and the next is 13.5% and 27.9%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.37%.

Volatility

Syneos Health’s last day, last week, and last month’s current intraday variation average was 0.18%, 1.18%, and 1.48%, respectively.

Syneos Health’s highest amplitude of average volatility was 2.33% (day), 2.26% (last week), and 3.22% (last month), respectively.

Syneos Health’s Stock Yearly Top and Bottom Value

Syneos Health’s stock is valued at $100.13 at 19:22 EST, under its 52-week high of $104.18 and way above its 52-week low of $66.01.

Syneos Health’s Moving Average

Syneos Health’s worth is higher than its 50-day moving average of $97.54 and way higher than its 200-day moving average of $89.35.

3. Anthem (ANTM)

15.2% sales growth and 15.84% return on equity

Anthem, Inc., through its subsidiaries, operates as a health benefits company in the United States.

Anthem’s sales growth this year is anticipated to be 13.6% and 9.5% for next year.

Year-on-year quarterly revenue growth grew by 15%, now sitting on 133.88B for the twelve trailing months.

Volume

Today’s last reported volume for Anthem is 1016410 which is 4.61% below its average volume of 1065550.

Anthem’s sales growth for the next quarter is 15.2%. The company’s growth estimates for the current quarter and the next is 52.4% and 105.1%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.84%.

Volatility

Anthem’s last day, last week, and last month’s current intraday variation average was 1.19%, 1.01%, and 1.36%, respectively.

Anthem’s highest amplitude of average volatility was 2.03% (day), 1.76% (last week), and 2.04% (last month), respectively.

Anthem’s Stock Yearly Top and Bottom Value

Anthem’s stock is valued at $452.14 at 19:22 EST, above its 52-week high of $439.90.

Anthem’s Moving Average

Anthem’s value is above its 50-day moving average of $413.11 and way above its 200-day moving average of $386.31.

Previous days news about Anthem(ANTM)

  • According to Bloomberg Quint on Thursday, 13 January, "Only 92 other publicly traded companies are in the $100 billion club, and even fewer — just CVS Health Corp., Walmart Inc. and Anthem Inc. — currently trade at a valuation below their sales."

4. Novo Nordisk A/S (NVO)

11.2% sales growth and 70.63% return on equity

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide.

Novo Nordisk A/S’s sales growth this year is expected to be 7.3% and 8.3% for next year.

Year-on-year quarterly revenue growth grew by 10.1%, now sitting on 129.91B for the twelve trailing months.

Volume

Today’s last reported volume for Novo Nordisk A/S is 1474280 which is 24.7% above its average volume of 1182170.

Novo Nordisk A/S’s sales growth for the next quarter is 11.2%. The company’s growth estimates for the current quarter and the next is 6.9% and 12.5%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 70.63%.

Volatility

Novo Nordisk A/S’s last day, last week, and last month’s current intraday variation average was 3.36%, 2.06%, and 1.51%, respectively.

Novo Nordisk A/S’s highest amplitude of average volatility was 2.28% (day), 1.94% (last week), and 2.07% (last month), respectively.

Novo Nordisk A/S’s Stock Yearly Top and Bottom Value

Novo Nordisk A/S’s stock is valued at $96.32 at 19:22 EST, way below its 52-week high of $115.95 and way higher than its 52-week low of $66.59.

Novo Nordisk A/S’s Moving Average

Novo Nordisk A/S’s worth is way under its 50-day moving average of $107.59 and higher than its 200-day moving average of $90.32.

5. Johnson & Johnson (JNJ)

10.4% sales growth and 26.81% return on equity

Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide.

Johnson & Johnson’s sales growth this year is expected to be 14.1% and 4% for next year.

Year-on-year quarterly revenue growth grew by 27.1%, now sitting on 89.19B for the twelve trailing months.

Volume

Today’s last reported volume for Johnson & Johnson is 7698430 which is 2.89% above its average volume of 7481650.

Johnson & Johnson’s sales growth is a negative 0% for the present quarter and 10.4% for the next. The company’s growth estimates for the current quarter and the next is 7.3% and 19.9%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 26.81%.

Volatility

Johnson & Johnson’s last day, last week, and last month’s current intraday variation average was 0.55%, 0.70%, and 0.61%, respectively.

Johnson & Johnson’s highest amplitude of average volatility was 0.88% (day), 1.05% (last week), and 1.09% (last month), respectively.

Johnson & Johnson’s Stock Yearly Top and Bottom Value

Johnson & Johnson’s stock is valued at $167.84 at 19:22 EST, under its 52-week high of $179.92 and way higher than its 52-week low of $142.86.

Johnson & Johnson’s Moving Average

Johnson & Johnson’s value is above its 50-day moving average of $162.51 and above its 200-day moving average of $167.48.

Previous days news about Johnson & Johnson(JNJ)

  • According to Bloomberg Quint on Wednesday, 12 January, "A South African Covid-19 vaccine trial will assess the safety and impact of varying doses of Johnson & Johnson and Pfizer Inc. shots as boosters for those infected with HIV as well as the wider population."
  • According to Benzinga on Thursday, 13 January, "The financing included lead investor Bios Partners; additional new investors Johnson & Johnson Innovation – JJDC, Inc., Kaitai Capital, PSQ Capital, and Michigan Capital Network Venture Fund III; and continuing investors InFocus Capital Partners, ExSight Ventures, the University of Michigan’s Michigan Investment in New Technology Startups (MINTS) program, Western Michigan University’s Biosciences Research & Commercialization Center, and the Capital Community Angels."
  • According to VentureBeat on Friday, 14 January, "For its series E round, Verana Health has attracted a slew of big-name strategic and institutional investors, including lead backers Johnson & Johnson Innovation and Novo Growth, as well as GV, Casdin Capital, Brook Byers, the Merck Global Health Innovation Fund, THVC, and Breyer Capital."

6. Good Life Advisors, LLC (ABB)

9.8% sales growth and 7.18% return on equity

ABB Ltd manufactures and sells electrification, industrial automation, motion, and robotics and discrete automation products for customers in utilities, industry and transport, and infrastructure worldwide.

Good Life Advisors, LLC’s sales growth this year is anticipated to be 13.5% and 5.5% for next year.

Year-on-year quarterly revenue growth grew by 21%, now sitting on 28.11B for the twelve trailing months.

Volume

Today’s last reported volume for Good Life Advisors, LLC is 2266640 which is 54.78% above its average volume of 1464420.

Good Life Advisors, LLC’s sales growth for the next quarter is 9.8%. The company’s growth estimates for the present quarter and the next is 90.5% and 57.7%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.18%.

Volatility

Good Life Advisors, LLC’s last day, last week, and last month’s current intraday variation average was 1.61%, 2.29%, and 1.32%, respectively.

Good Life Advisors, LLC’s highest amplitude of average volatility was 1.57% (day), 1.24% (last week), and 1.03% (last month), respectively.

Good Life Advisors, LLC’s Stock Yearly Top and Bottom Value

Good Life Advisors, LLC’s stock is valued at $37.35 at 19:22 EST, below its 52-week high of $38.03 and way higher than its 52-week low of $26.31.

Good Life Advisors, LLC’s Moving Average

Good Life Advisors, LLC’s value is way above its 50-day moving average of $33.83 and higher than its 200-day moving average of $34.95.

7. Cummins (CMI)

6.5% sales growth and 26.44% return on equity

Cummins Inc. designs, manufactures, distributes, and services diesel and natural gas engines, products worldwide.

Cummins’s sales growth this year is anticipated to be 23% and 7% for next year.

Year-on-year quarterly revenue growth grew by 58.6%, now sitting on 23.15B for the twelve trailing months.

Volume

Today’s last reported volume for Cummins is 1017510 which is 5.88% above its average volume of 961004.

Cummins’s sales growth is a negative 0% for the ongoing quarter and 6.5% for the next. The company’s growth estimates for the ongoing quarter and the next is 15.1% and 19.3%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 26.44%.

Volatility

Cummins’s last day, last week, and last month’s current intraday variation average was 0.66%, 1.38%, and 1.07%, respectively.

Cummins’s highest amplitude of average volatility was 3.00% (day), 2.72% (last week), and 2.43% (last month), respectively.

Cummins’s Stock Yearly Top and Bottom Value

Cummins’s stock is valued at $237.54 at 19:22 EST, way under its 52-week high of $277.09 and way above its 52-week low of $209.09.

Cummins’s Moving Average

Cummins’s value is higher than its 50-day moving average of $231.34 and below its 200-day moving average of $243.42.

LEAVE A REPLY

Please enter your comment!
Please enter your name here